Skip to content
Screener

Immunome IMNM Q4 2025 Annual earnings

Reported March 3, 2026 · Before market open

Revenue-
EPS-$0.75Miss by $0.16
EPS estimate-$0.59

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$181.8K
EPS estimate-$0.64

Financials

Q4 2025

Income statement

See full
Revenue--100%
Operating income-$72.9M+12.2%
Net income-$69.9M+12.9%
EPS (diluted)-$0.75+41.4%

Balance sheet

See full
Cash & equivalents$653.5M+356%
Total debt$3.9M-20.2%
Total equity$634.3M+250%
Total assets$683.2M+184%

Cash flow

See full
Operating cash flow-$48.0M-14.0%
CapEx$4.0M+255%
Free cash flow-$52.0M-20.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.37B+258%
Enterprise value$1.72B+228%
P/S341.4×+268×

Profitability

See full
Operating margin-3,228.8%-140pp
Net margin-3,060%-161pp
FCF margin-2,890.1%-16,333pp

Returns & leverage

See full
Return on equity-52.1%-22.0pp
Debt / equity0×0.0×
Current ratio14.7×+10.6×

FAQ

When did Immunome report Q4 2025 earnings?
Immunome (IMNM) reported Q4 2025 earnings on March 3, 2026 before market open.
What were Immunome's Q4 2025 revenue and EPS?
Immunome reported revenue of - and eps of $-0.75 for Q4 2025.
Did Immunome beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.59 by $0.16.
How did Immunome's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $2.7M a year earlier and eps grew 10.7% from $-0.84.
Where can I find Immunome's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-088141) and the 10-K periodic report (0001193125-26-088172) directly on SEC EDGAR. The filing index links above go to sec.gov.